No Data
No Data
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell
Immutep (IMMP) said late Thursday it achieved "positive" results from cohort B of the TACTI-003 phase 2b trial evaluating the company's eftilagimod alfa in combination with Merck's (MRK) Keytruda as a potential first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma in patients with negative PD-L1 expression.
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
During the last three months, 6 analysts shared their evaluations of Merck & Co (NYSE:MRK), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent ratings,
Merck Is Maintained at Equal-Weight by Morgan Stanley
Merck Is Maintained at Equal-Weight by Morgan
Merck & Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 4.86% Morgan Stanley $132 → $134 Maintains Equal-Weight 06/20/2024 21.29% Cantor Fitzgerald $15
United Therapeutics Cut at Morgan Stanley on Risk-reward Setup
Express News | Merck & Co Inc : Morgan Stanley Raises Target Price to $134 From $132
No Data
White_Shadow :
104749672 : Informative
Mathew Yetter White_Shadow: T hey are both pigs!
aaron1999x : Trump FtW
71780680 : why would anyone want more[Sigh]...seams to me people like the kolaid
View more comments...